Reaction
Tumour Associated Fever reporting signals
As of the last recalculation, Tumour Associated Fever appears in 395 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is PEMBROLIZUMAB (PRR 47.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pembrolizumab | 77 | 47.7 | 47.7 |
| Pemetrexed | 16 | 40.9 | 41.0 |
| Regorafenib | 8 | 37.0 | 37.1 |
| Pemetrexed Disodium | 25 | 36.8 | 36.9 |
| Meropenem | 21 | 36.4 | 36.4 |
| Piperacillin Sodium,Tazobactam Sodium | 16 | 33.1 | 33.1 |
| Nivolumab | 47 | 28.9 | 29.0 |
| Azacitidine For | 9 | 26.7 | 26.7 |
| Gemcitabine Hydrochloride | 25 | 26.4 | 26.4 |
| Azacitidine | 14 | 25.7 | 25.8 |
| Blinatumomab | 5 | 25.6 | 25.6 |
| Erlotinib | 4 | 22.0 | 22.0 |
| Ipilimumab | 17 | 21.6 | 21.6 |
| Erlotinib Hydrochloride | 5 | 21.3 | 21.3 |
| Lenvatinib | 11 | 18.1 | 18.2 |
| Axicabtagene Ciloleucel | 3 | 16.1 | 16.1 |
| Atezolizumab | 11 | 15.3 | 15.3 |
| Cabozantinib | 12 | 13.5 | 13.5 |